The open-label Phase 3 trial evaluated the safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne over a 40-week period. Denifanstat is being developed by Ascletis for acne in ...
-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 This Phase III clinical trial is a randomized, double-blind, ...
Hormonal acne affects millions of people well beyond their teenage years, creating frustrating breakouts that seem impossible to control. Unlike typical acne that responds well to standard treatments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results